Scenarios that move GILD
Gilead Sciences, Inc. - Common Stock
Scenarios that move GILD: 9 analyses, 2 positive, 7 negative.
- · RARE's Fayuvi approval triggers second $203 million PRV sale — ▼ · impact -29 · confidence low · horizon quarters
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▼ · impact -12 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▼ · impact -12 · confidence medium · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -35 · confidence low · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▼ · impact -40 · confidence high · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +35 · confidence low · horizon weeks
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▼ · impact -13 · confidence medium · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -45 · confidence low · horizon quarters
- · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +37 · confidence medium · horizon weeks